Provider & country due diligence
Swiss Medica due diligence
Swiss Medica due diligence — Product, evidence and regulatory checks
Open →EmCell due diligence
EmCell due diligence — Product, evidence and regulatory checks
Open →DVC Stem due diligence
DVC Stem due diligence — Product, evidence and regulatory checks
Open →Stem Cell Institute due diligence
Stem Cell Institute due diligence — Product, evidence and regulatory checks
Open →ANOVA / German clinics due diligence
ANOVA / German clinics due diligence — Product, evidence and regulatory checks
Open →Giostar due diligence
Giostar due diligence — Product, evidence and regulatory checks
Open →Bulgaria and USA
Bulgaria and USA — Compare legal routes and verification sources
Open →Bulgaria and UK
Bulgaria and UK — Compare legal routes and verification sources
Open →Bulgaria and Germany
Bulgaria and Germany — Compare legal routes and verification sources
Open →Bulgaria and Switzerland
Bulgaria and Switzerland — Compare legal routes and verification sources
Open →Bulgaria and Mexico
Bulgaria and Mexico — Compare legal routes and verification sources
Open →Bulgaria and India
Bulgaria and India — Compare legal routes and verification sources
Open →Bulgaria and Serbia
Bulgaria and Serbia — Compare legal routes and verification sources
Open →Bulgaria and Turkey
Bulgaria and Turkey — Compare legal routes and verification sources
Open →Bulgaria and Thailand
Bulgaria and Thailand — Compare legal routes and verification sources
Open →Bulgaria and Panama
Bulgaria and Panama — Compare legal routes and verification sources
Open →Browse comparisons
- ANOVA / German clinics: claims, evidence and regulatory questions
- Premium pricing meets cautious regulation: Bulgaria vs Germany (2026)
- Cost leadership comes with quality variability: Bulgaria vs India (2026)
- Proximity masks regulatory uncertainty: Bulgaria vs Mexico (2026)
- Americas hub combines access and regulation gaps: Bulgaria vs Panama (2026)
- Non-EU clinic with growing reputation: Bulgaria vs Serbia (2026)
- Wealth meets innovation in highest-cost market: Bulgaria vs Switzerland (2026)
- Medical tourism pioneer faces standardisation questions: Bulgaria vs Thailand (2026)
- Growing hub balances cost and expansion: Bulgaria vs Turkey (2026)
- NHS limitation drives private exploration: Bulgaria vs the UK (2026)
- FDA caution meets private clinic reality: Bulgaria vs the USA (2026)
- DVC Stem: claims, evidence and regulatory questions
- EmCell: claims, evidence and regulatory questions
- Giostar: claims, evidence and regulatory questions
- MSC vs exosomes for Alzheimer's Disease: what the registries show
- MSC vs exosomes for Arterial Hypertension: what the registries show
- MSC vs exosomes for Autism Spectrum Disorder: what the registries show
- MSC vs exosomes for Parkinson's Disease: what the registries show
- MSC vs HSCT for ALS (Motor Neurone Disease): what the registries show
- MSC vs HSCT for Anemia: what the registries show
- MSC vs HSCT for Chronic Kidney Disease: what the registries show
- MSC vs HSCT for Liver Cirrhosis: what the registries show
- MSC vs HSCT for Crohn's & IBD: what the registries show
- MSC vs HSCT for Diabetes (Type 1 & 2): what the registries show
- MSC vs HSCT for Heart Failure & Cardiac Repair: what the registries show
- MSC vs HSCT for Lupus (SLE): what the registries show
- MSC vs HSCT for Multiple Sclerosis: what the registries show
- MSC vs HSCT for Rheumatoid Arthritis: what the registries show
- MSC vs HSCT for Scleroderma (Systemic Sclerosis): what the registries show
- MSC vs HSCT for Spinal Cord Injury: what the registries show
- MSC vs HSCT for Stroke Recovery: what the registries show
- MSC vs PRP for Erectile Dysfunction: what the registries show
- MSC vs PRP for Knee Osteoarthritis: what the registries show
- MSC vs PRP for Peripheral Neuropathy: what the registries show
- MSC vs PRP for Premature Ovarian Insufficiency: what the registries show
- MSC vs PRP for Chronic Wounds & Ulcers: what the registries show
- Stem Cell Institute: claims, evidence and regulatory questions
- Swiss Medica: claims, evidence and regulatory questions